Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Inrebic (fedratinib dihydrochloride monohydrate) — Bristol Myers Squibb Pharma EEIG
The EMA authorises Inrebic (fedratinib dihydrochloride monohydrate) for myeloproliferative disorders, including primary myelofibrosis, with …
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Results: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis [Phase 3]
Phase III study of SAR302503 in intermediate-2 and high-risk myelofibrosis was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-08-04Clinical Trial Results: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety, PK/PD, and dose escalation/expansion of PXS-5505 in patients with myelofibrosis (including PMF and post-P…
-
CLINICAL_TRIALS trial_result · 2026-07-16Clinical Trial Results: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Phase 2]
Phase II open-label single-arm trial of SAR302503 in myelofibrosis patients previously treated with ruxolitinib.
-
CLINICAL_TRIALS trial_result · 2026-07-09Clinical Trial Results: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]
Phase 2 trial evaluating ruxolitinib before, during, and after hematopoietic stem cell transplantation in patients with primary or secondary…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in hematologic and myeloproliferative malignancies; study complete…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [Phase 1, Phase 2]
The Phase 1/2 study evaluating the combination of ruxolitinib and CPX-351 in advanced phase myeloproliferative neoplasms was terminated, wit…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating the efficacy, safety, and pharmacokinetics of TQ05105 tablets in intermediate/high-risk myelofibrosis is n…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis [NA]
A feasibility clinical trial evaluating extracorporeal iron purification as a treatment approach for patients with myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Therapeutic RSK1 Targeting in Myelofibrosis [Phase 1]
A Phase 1 clinical trial update focusing on a therapy targeting RSK1 for myelofibrosis, which is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis [Phase 2]
This update describes a Phase 2 study evaluating momelotinib in combination with luspatercept for transfusion-dependent myelofibrosis; the t…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis [Phase 2, Phase 3]
A clinical trial update notes that luspatercept is being evaluated in Phase 2/Phase 3 studies to prevent poor erythroid engraftment in patie…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Extended Access of Momelotinib in Adults With Myelofibrosis [Phase 2]
This clinical trial update notes extended-access use of momelotinib in adults with myelofibrosis, including primary myelofibrosis and relate…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) [Phase 1]
The update reports on tolerability of adding Ropeginterferon alfa-2b to ongoing ruxolitinib therapy in patients with myelofibrosis in a Phas…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) [Phase 3]
This Phase 3 trial evaluates pelabresib in combination with ruxolitinib for myelofibrosis and is currently recruiting across primary MF and …
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms [Phase 1]
This clinical trial update announces a Phase 1 study of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms and indicates the trial i…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis [Phase 2]
Phase 2 clinical trial update on peritransplant ruxolitinib for patients with primary or secondary myelofibrosis, currently active but not r…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers [Phase 1]
ZE74-0282 is the subject of a Phase 1 trial for JAK2 V617F-positive blood cancers, including polycythemia vera and myelofibrosis, and the st…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial is evaluating oral Nuvisertib (TP-3654) in patients with myelofibrosis and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis [Phase 2]
A Phase 2 clinical study is evaluating the combination of ruxolitinib and thalidomide for patients with myelofibrosis; the trial status is a…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy [Phase 1]
Phase 1 clinical trial sponsored by the University of Alabama at Birmingham evaluating UAB 2419-CD34 selection using the CliniMACS Prodigy s…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) [Phase 2]
A Phase 2 randomized trial evaluating ASTX727 with or without iadademstat in advanced myeloproliferative neoplasms, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis [Phase 3]
A Phase 3 clinical trial update evaluating the combination of selinexor and ruxolitinib for myelofibrosis; the study is currently active but…